# Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

**Anthony R. Mato,[1] Meghan Thompson,[2] John N. Allan,[3] Danielle M. Brander,[4] John M. Pagel,[5] Chaitra S. Ujjani,[6] Brian T. Hill,[7] Nicole Lamanna,[8] Frederick Lansigan,[9] Ryan Jacobs,[10] Mazyar Shadman,[11] Alan P. Skarbnik,[12] Jeffrey J. Pu,[13] Paul M. Barr,[14] Alison R. Sehgal,[15] Bruce D. Cheson,[6] Clive S. Zent,[14] Hande H. Tuncer,[16] Stephen J. Schuster,[2] Peter V. Pickens,[17] Nirav N. Shah,[18] Andre Goy,[12] Allison M. Winter,[7] Christine Garcia,[15] Kaitlin Kennard,[2] Krista Isaac,[19] Colleen Dorsey,[2] Lisa M. Gashonia,[2] Arun K. Singavi,[18] Lindsey E. Roeker,[1] Andrew Zelenetz,[1] Annalynn Williams,[14] Christina Howlett,[12] Hanna Weissbrot,[8] Naveed Ali,[17] Sirin Khajavian,[11] Andrea Sitlinger,[4] Eve Tranchito,[7] Joanna Rhodes,[2] Joshua Felsenfeld,[3] Neil Bailey,[5] Bhavisha Patel,[20] Timothy F. Burns,[9] Melissa Yacur,[13] Mansi Malhotra,[16] Jakub Svoboda,[2] Richard R. Furman[3] and Chadi Nabhan[21]**

*ARM and MT contributed equally to this work.*

[1]CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; [2]Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; [3]New York Presbyterian & Weill Cornell, NY; [4]Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC; [5]Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA; [6]Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC; [7]Taussig Cancer Institute, Cleveland Clinic Foundation, OH; [8]Columbia University Medical Center, New York, NY; [9]Dartmouth-Hitchcock Medical Center, Lebanon, NH; [10]Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC; [11]University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA; [12]John Theurer Cancer Center, Hackensack Meridian Health, NJ; [13]Penn State Health, Hershey, PA; [14]Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY; [15]University of Pittsburgh Medical Center, PA; [16]Tufts Medical Center, Boston, MA; [17]Abington Hem. Onc. Assoc., Inc., Willow Grove, PA; [18]Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI; [19]Internal Medicine, Lankenau Medical Center, Wynnewood, PA; [20]Washington Hospital Center, DC and [21]Cardinal Health, Dublin, OH, USA

 doi:10.3324/haematol.2018.193615

Received: March 17, 2018.

Accepted: June 5, 2018.

Pre-published: June 7, 2018.

Correspondence: matoa@mskcc.org

**Supplemental Data.**

**Supplemental Table 1. Venetoclax dosing and select toxicities**

| | |
|---|---|
| Maximum dose achieved during ramp-up | 85.1% achieved 400 mg (n=120/141) |
| Stable dose following ramp-up | 75.2% achieved 400 mg (n=103/137) |
| Dose interruptions | 29.6% required ≥1 dose interruption (n=40/135) |
| Dose reductions | 20.5% required ≥1 dose reduction (n=24/117) |
| Neutropenia (ANC<1000) | 47.4% (n=65/137) |
| Thrombocytopenia (platelets <50,000) | 36.0% (n=49/136) |
| Diarrhea (>7 bowel movements/day) | 7.3% (n=10/138) |
| Neutropenic fever | 11.6% (n=16/138) |
| TLS (laboratory and clinical) | 12.2% (n=17/139) |

**Supplemental Table 2. Hospitalization during dose escalation**

| **Number of hospitalization** | **Low risk N=58** | | **Intermediate risk N=48** | | **High risk N=25** | |
|---|---|---|---|---|---|---|
| | **%** | **n** | **%** | **n** | **%** | **n** |
| **0** | 34.5% | 20 | 14.6% | 7 | 0 | 0 |
| **1** | 20.7% | 12 | 29.2% | 14 | 12.0% | 3 |
| **2** | 25.9% | 15 | 41.7% | 20 | 32.0% | 8 |
| **3** | 5.2% | 3 | 6.3% | 3 | 20.0% | 5 |
| **4** | 5.2% | 3 | 4.2% | 2 | 4.0% | 1 |
| **5** | 8.6% | 5 | 4.2% | 2 | 32.0% | 8 |

**Supplemental Table 3. Second and third treatments following venetoclax**

| |
|---|
| **Second treatment after venetoclax and response:**<br>n=7 patients<br>• Allogeneic SCT: CR<br>• HyperCVAD: PD<br>• Venetoclax + ibrutinib + Obinutuzumab: PD<br>• Ibrutinib + venetoclax: PD<br>• CAR + ibrutinib: PD<br>• PI3K inhibitor: PD<br>• Other: SD |
| **Third treatment after venetoclax and response**<br>n=5 patients<br>• CAR-T (2): 1 SD, 1 CR<br>• Venetoclax + ibrutinib + rituximab: SD<br>• R-CHOP: PD<br>• Other: PD |

**Supplemental Figure 1. Overall survival by TP53 status.** OS is similar for patients with intact *TP53* and patients with *TP53* interruption, either *TP53* mutation or del(17p).


OS by TP53 status
1.00
0.75
0.50
0.25
0.00
0
10
20
30
40
Months
TP53 intact
TP53 interrupted